Wedbush Reiterates “Outperform” Rating for Tyra Biosciences (NASDAQ:TYRA)

Tyra Biosciences (NASDAQ:TYRA)‘s stock had its “outperform” rating reiterated by research analysts at Wedbush in a research note issued to investors on Thursday,RTT News reports. They currently have a $30.00 price objective on the stock. Wedbush’s target price points to a potential upside of 110.82% from the company’s previous close.

TYRA has been the subject of a number of other research reports. Wall Street Zen upgraded Tyra Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, October 4th. Raymond James Financial initiated coverage on Tyra Biosciences in a research report on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Friday, August 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Wednesday, October 8th. Finally, Oppenheimer restated an “outperform” rating and issued a $36.00 price objective on shares of Tyra Biosciences in a report on Wednesday, September 10th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $32.00.

Tyra Biosciences Trading Down 4.0%

TYRA stock traded down $0.59 during trading on Thursday, hitting $14.23. The company had a trading volume of 83,894 shares, compared to its average volume of 283,445. The company has a fifty day moving average price of $13.52 and a two-hundred day moving average price of $11.39. The company has a market cap of $758.46 million, a P/E ratio of -7.99 and a beta of 1.12. Tyra Biosciences has a fifty-two week low of $6.42 and a fifty-two week high of $17.78.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, meeting the consensus estimate of ($0.50). On average, analysts expect that Tyra Biosciences will post -1.57 earnings per share for the current year.

Hedge Funds Weigh In On Tyra Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Tyra Biosciences in the first quarter worth $84,000. US Bancorp DE increased its holdings in Tyra Biosciences by 50.5% during the first quarter. US Bancorp DE now owns 5,435 shares of the company’s stock worth $51,000 after buying an additional 1,823 shares during the last quarter. Swiss National Bank raised its position in Tyra Biosciences by 42.0% in the first quarter. Swiss National Bank now owns 29,400 shares of the company’s stock worth $273,000 after acquiring an additional 8,700 shares during the period. Nuveen LLC purchased a new stake in shares of Tyra Biosciences during the 1st quarter worth approximately $465,000. Finally, American Century Companies Inc. raised its holdings in shares of Tyra Biosciences by 5.8% in the 1st quarter. American Century Companies Inc. now owns 23,431 shares of the company’s stock worth $218,000 after purchasing an additional 1,289 shares during the period. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.